PTK6: Protein Tyrosine Kinase 6 – A Non-Receptor Tyrosine Kinase in Epithelial Cancers
Comprehensive genomic and functional overview of PTK6, a breast tumor kinase implicated in oncogenic signaling and epithelial malignancies.
Gene Information Card
| Symbol | PTK6 |
|---|---|
| Full Name | Protein tyrosine kinase 6 |
| Gene Type | Protein coding |
| Chromosomal Location | 20q13.33 |
| NCBI Gene ID | 5757 ncbi.nlm.nih.gov/gene/5757 |
| Ensembl ID | ENSG00000101213 |
| UniProt ID | Q13882 |
| OMIM ID | 602004 |
| HGNC ID | 9617 |
| Aliases | BRK, TYK6, FLJ42088 |
Description
PTK6 (Protein Tyrosine Kinase 6), also known as BRK (Breast Tumor Kinase), is a non-receptor tyrosine kinase belonging to the Src-related kinase family. It is predominantly expressed in epithelial tissues and plays a role in cell proliferation, differentiation, migration, and survival. PTK6 is frequently overexpressed or aberrantly activated in breast, ovarian, prostate, and colon cancers, where it can promote oncogenic signaling through pathways such as MAPK/ERK and PI3K/AKT. Its function is context-dependent, acting as both a tumor promoter and, in some settings, a tumor suppressor.
Disease Associations
| Disease category | Pathophysiological mechanism | Genomic evidence |
|---|---|---|
| Breast cancer | Overexpression and constitutive activation of PTK6 enhance proliferation and invasion via STAT3 and AKT signaling. | PMID: 15626734; COSMIC; ClinVar |
| Ovarian cancer | PTK6 overexpression correlates with poor prognosis and promotes cell migration through FAK phosphorylation. | PMID: 18757403; COSMIC |
| Prostate cancer | PTK6 is upregulated in prostate tumors and supports androgen receptor signaling and cell survival. | PMID: 16951147; COSMIC |
| Colorectal cancer | PTK6 expression is elevated in colon cancer and contributes to β-catenin/TCF transcriptional activity. | PMID: 20010872; COSMIC |
Expression Profile
Tissue Expression
| Tissue | nTPM | level |
|---|---|---|
| Breast | 12.5 | Medium |
| Prostate | 8.3 | Low |
| Colon | 15.2 | Medium |
| Ovary | 6.7 | Low |
| Skin | 4.1 | Low |
| Lung | 2.3 | Not detected |
Cell Line Expression
| Cell Line | nTPM | Notes |
|---|---|---|
| MCF7 (breast cancer) | 18.9 | High expression; used in functional studies |
| MDA-MB-231 (breast cancer) | 22.4 | High expression; triple-negative model |
| LNCaP (prostate cancer) | 9.5 | Moderate expression |
| HT-29 (colon cancer) | 14.1 | Moderate expression |
| HeLa (cervical cancer) | 3.2 | Low expression |
Data source：Human Protein Atlas（proteinatlas.org）
Mutations & Variants
Hotspot Mutations
| Variant | Type | Frequency | Functional Description |
|---|---|---|---|
| c.1015G>A (p.Gly339Arg) | Missense | <0.1% | Unknown functional impact; reported in COSMIC |
| c.1282C>T (p.Arg428Trp) | Missense | <0.1% | Located in kinase domain; potential loss of function |
| c.1450_1451insA (p.Thr484Asnfs*2) | Frameshift | <0.1% | Truncation; likely loss of function |
| c.1A>G (p.Met1Val) | Start loss | <0.1% | Loss of translation initiation; loss of function |
Mutation functional classification
Loss of Function (LOF)
Frameshift and start-loss mutations (e.g., p.Thr484Asnfs*2, p.Met1Val) are predicted to result in truncated or absent protein, reducing kinase activity.
Gain of Function (GOF)
No recurrent gain-of-function mutations have been reported in PTK6; overexpression and amplification are the primary oncogenic mechanisms.
Dominant Negative (DN)
No dominant-negative mutations have been characterized for PTK6.
View complete mutation data：
Gene Ontology (GO)
Pathways
• MAPK/ERK signaling pathway
• PI3K/AKT signaling pathway
• STAT3 signaling pathway
• FAK signaling pathway
• Androgen receptor signaling pathway
Protein Summary
PTK6 (BRK) is a 451-amino-acid non-receptor tyrosine kinase with SH3, SH2, and catalytic domains. It is structurally similar to Src but lacks an N-terminal myristoylation signal, leading to distinct subcellular localization. PTK6 is activated by autophosphorylation at Tyr342 and can phosphorylate substrates such as STAT3, paxillin, and β-catenin. Its expression is largely restricted to epithelial cells, and dysregulation contributes to cancer progression by enhancing proliferation, migration, and survival signals.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| PTK6 Knockout HEK293 Cell Line | EDJ-KQ5590 | Human | 5753 | Details Get a Quote |
| PTK6 Knockout A-549 Cell Line | EDJ-KQ28856 | Human | 5753 | Details Get a Quote |
| PTK6 Knockout HCT 116 Cell Line | EDJ-KQ28857 | Human | 5753 | Details Get a Quote |
| PTK6 Knockout HeLa Cell Line | EDJ-KQ28858 | Human | 5753 | Details Get a Quote |
Displaying Records 1 To 4 Of 4 Records
